MedPath

Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A)

Not Applicable
Conditions
on-small cell lung cancer (non-squamous cell carcinoma)
Registration Number
JPRN-UMIN000006243
Lead Sponsor
orth-East Japan study group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. Clinically ineligible interstitial pneumonitis 2. Episode of hemoptysis 3. With brain metastasis, or tumor with large vessel invation or cavity formation 4. With active gastrointestinal ulcer 5. With severe comorbidities 6. With inadequate conditions judged by the attending physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath